Featured Articles

AstraZeneca’s Fasenra (benralizumab) has been approved in the US for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA). EGPA is a rare,…
Read More...

Amneal Pharmaceuticals, Inc. and Shilpa Medicare Limited announced U.S. Food and Drug Administration (FDA) approval of BORUZU, a new presentation of bortezomib for ready-to-use…
Read More...

Evotec SE and X-Chem, leader in DNA-encoded library (DEL) technology, announced a collaboration agreement focused on accelerating early-stage drug discovery. X-Chem’s DEL technology …
Read More...

Merck, known as MSD outside of the United States and Canada, announced that the European Commission (EC) has approved KEYTRUDA (pembrolizumab), Merck’s anti-PD-1 therapy, in combination…
Read More...

Eli Lilly and Company announced Zepbound (tirzepatide) 2.5 mg and 5 mg single-dose vials are available for self-pay for patients with an on-label prescription, significantly expanding…
Read More...

Pfizer Inc. introduced PfizerForAll , a user-friendly digital platform designed to make access to healthcare and managing health and wellness more seamless for people across the U.S.…
Read More...

Roche announced that the European Commission has approved PiaSky (crovalimab), a novel recycling monoclonal antibody that inhibits the complement protein C5, for adults and adolescents…
Read More...

Eli Lilly and Company announced the opening of the Lilly Seaport Innovation Center (LSC), a research and development facility in the Boston Seaport dedicated to advancing Lilly's…
Read More...

AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has received conditional approval in China as a monotherapy for the treatment of adult patients with locally advanced…
Read More...

Pfizer Inc. announced positive top-line safety and immunogenicity results from substudy B of the ongoing pivotal Phase 3 clinical trial ( NCT05842967 ) MONeT (RSV I Mmunizati ONStudy…
Read More...

GSK Singapore announced that the Singapore Health Sciences Authority (HSA) has approved a new indication for Jemperli (dostarlimab), which may now be used in combination with…
Read More...

Daiichi Sankyo and Merck, known as MSD outside of the United States and Canada, have expanded their existing global co-development and co-commercialization agreement for three…
Read More...

Sangamo Therapeutics, Inc., a genomic medicine company, announced it has entered into a license agreement with Genentech, a member of the Roche Group, to develop intravenously…
Read More...

Roche announced the completion of the acquisition of LumiraDx’s Point of Care technology, following the receipt of all required antitrust and regulatory clearances. Roche will now…
Read More...

Today marks a significant step for Boehringer Ingelheim’s immuno-oncology pipeline as the company is adding an innovative preclinical program with the acquisition of Nerio…
Read More...

Novartis announced that Scemblix (asciminib) has been granted Priority Review status by the US Food and Drug Administration (FDA) for treatment of newly diagnosed adult patients with…
Read More...

The Phase III ARANOTE trial, investigating NUBEQA (darolutamide) plus androgen deprivation therapy (ADT) in patients with metastatic hormone-sensitive prostate cancer (mHSPC),…
Read More...

Merck, a leading science and technology company, announced the start of commercial production of its first GMP (Good Manufacturing Practices) compliant manufacturing line for cell…
Read More...

Evotec SE announced it has entered into a multi-year master research collaboration and option and license agreement with Pfizer. Under the agreement, Evotec and Pfizer will initially…
Read More...

Johnson & Johnson announced that it has successfully completed the acquisition of Yellow Jersey, a demerged subsidiary of Numab Therapeutics to secure the global rights to NM26, a …
Read More...